Company news, research breakthroughs, and major announcements across industries.

Home/Science

Science

TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026

TGT_Logo_jpeg_RGB_PMS_368_Green_-_PMS_2145_Blue.jpg
TGT_Logo_jpeg_RGB_PMS_368_Green_-_PMS_2145_Blue.jpg

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced several updated poster presentations at MSToronto2026, the 10th Joint ACTRIMS-ECTRIMS Meeting. The presentations include seven-year follow up data from the ULTIMATE I & II trials, Phase 1 subcutaneous BRIUMVI data, Phase 3 ENHANCE trial data, an update from the ENABLE real world study, and more presentations highlighting BRIUMVI data. Additionally, the abstract is now available for the late-breaking oral presen...

  • PublishedOctober 21, 2026 · 8:52 AM
  • LocationNEW YORK
  • IndustryScience
  • LanguageEN

Published by Business Wire. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization